Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Not applicable

A Brief Intervention by Nurses to Reduce the Prescribing of Occluded Peripheral Venous Catheters in the Emergency Department

NCT07584590 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2026-06-01
Last updated
2026-05-13

Condition(s) studied

an Initial Order for a Blood Draw and Placement of an IV Line in the Emergency Department

Investigational drug(s) / intervention(s)

question for the prescriber

question for the prescriber: Once the nurse has received the doctor's order for a blood draw with a KTO, she will ask the prescribing physician: Is the KTO being prescribed for: the administration of medication? The injection of a contrast agent? A second blood draw? For each question, there are three possible answers: Yes? No? Maybe?

Study summary

Peripheral venous catheters are frequently inserted in hospitals, with approximately 25 million placed annually in France (HAS data, 2005). The occluded peripheral venous catheter with extension tubing has become the standard in some emergency departments, offering advantages such as patient mobility, the ability to perform repeated blood draws, and the administration of intravenous medications. A 2018 meta-analysis revealed that one in three devices was unnecessary. The placement of a occluded peripheral venous is associated with a more painful insertion, higher cost, and an increased risk of infection and thromboembolism, and blood samples obtained via the occluded peripheral venous catheter are more often hemolyzed than those obtained by direct venipuncture.

Communication between physicians and nurses is essential to ensure optimal patient care. A brief intervention by the nurse when a physician prescribes a occluded peripheral venous catheter can help clarify the appropriateness of this prescription, which could lead to reduced pain for the patient, time savings for healthcare providers, and material cost savings for the hospital.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients assigned a triage score of 3A, 3B, or 4 according to the French triage scale, or 3 or 4 according to the CIMU triage scale, by the triage nurse * Patients with a blood draw order involving the placement of an occluded catheter * Age 18 years or older * Patients who have read and understood the information sheet * Patients who have given their verbal consent to participate in the study * Patients enrolled in a social security program Exclusion Criteria: * Patients admitted to the emergency department with a pre-existing intravenous line * Patients treated by the Mobile Emergency and Resuscitation Unit outside the hospital * Patients with a blocked catheter who did not undergo an initial blood draw * Patient with known neurocognitive disorders incompatible with informed consent * Pregnant or breastfeeding woman * Patient under legal guardianship (guardianship or conservatorship) or patient deprived of liberty * Patient refusing to participate in the study * Patient participating in another interventional research study

Primary outcome measure(s)

  • the proportion of obturator catheters placed improperly — day 1
    Questions for the prescriber

Trial sites (16)

FacilityCityRegionStatus
CHU Amiens Amiens France
CHU Angers Angers France
Chu Clermont Ferrand Clermont-Ferrand France
APHP Henri Mondor Créteil France
Ch Dieppe Dieppe France
APHP CH Simone Veil Eaubonne France
HCL Lyon Sud Lyon France
HIA Laveran Marseille Marseille France
CHRU Nancy Nancy France
CHU Nantes Nantes France
APHP Lariboisière Paris France
AP HP Pitié Salpétrière Paris France
APHP Bichat Paris France
APHP St Antoine Paris France
CHU de ROUEN Rouen France
Chu Toulouse Toulouse France
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07584590 on ClinicalTrials.gov ↗ ← All trials in France